The document is an intimation for an earnings call, which is an Investor's Conference Call.
The event is scheduled for Thursday, 5th November 2026, at 12:00 noon IST.
The stated purpose of the call is to discuss the Company's financial results and performance for the second quarter and half year ended 30th September 2026.
The company will announce its results on Wednesday, 4th November 2026, meaning the call is scheduled after the earnings announcement.
The call will be led by the senior management, though no specific names or designations are provided in the intimation.
The results will be made available on the company's website: www.smspharma.com.
The document is a regulatory filing pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; it contains standard compliance language but does not explicitly state that no unpublished price sensitive information (UPSI) will be shared.
Additional Notes Section
The intimation includes comprehensive dial-in information for participants, including universal numbers for India and international toll-free numbers for Hong Kong, Singapore, UK, and US.
A Diamond Pass pre-registration link is provided: https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7232453&linkSecurityString=40abed38d9.
Contact details for the company's compliance officer and its investor relations team (Eqsponent) are included.
No financial data, guidance, or strategic updates were disclosed in this announcement; it is purely a notice for the upcoming event.
